iCAD (NASDAQ:ICAD) Stock Price Crosses Above 200-Day Moving Average – Here’s Why

Shares of iCAD, Inc. (NASDAQ:ICAD) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.57 and traded as high as $1.78. iCAD shares last traded at $1.78, with a volume of 282,089 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a report on Thursday, November 21st.

iCAD Trading Up 0.6 %

The company has a market capitalization of $47.51 million, a PE ratio of -13.77 and a beta of 1.43. The stock’s fifty day moving average is $1.81 and its two-hundred day moving average is $1.58.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in iCAD stock. Essex LLC bought a new position in shares of iCAD, Inc. (NASDAQ:ICAD) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned 0.52% of iCAD as of its most recent SEC filing. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.